title: Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.
abstract: Chemotherapy-induced polyneuropathy (CIPN) is a common, but underestimated, clinical challenge. Incidence varies depending on many factors that are equally as important as the type of chemotherapeutic agent itself. Moreover, the assessment of CIPN is still uncertain, as several of the most frequently used scales do not rely on a formal neurological evaluation and depend on patients' reports and examiners' interpretations. Therefore, the aim of this MiniReview was to introduce the most common chemotherapies that cause neuropathy, and in addition to this, highlight the most significant differences between the neuropathic pain scales, which are most commonly used for assessing CIPN.
authors.affiliation: Department of Oncology, Lillebaelt Hospital, Vejle, Denmark.
authors.forename: Ahmed H
authors.initials: AH
authors.lastname: Zedan
authors.forename: Ole J
authors.initials: OJ
authors.lastname: Vilholm
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D020258:Neurotoxicity Syndromes / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D010147:Pain Measurement; D011115:Polyneuropathies / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents